×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. We are committed to safeguarding your information and ensuring the highest standards of data protection. Your trust and privacy are of utmost importance to us.

EMA recommends new diabetes treatments for approval

  858 Views

eMediNexus    28 January 2018

The European Medicines Agencys (EMAs) Committee for Medicinal Products for Human Use (CHMP) has recommended for approval a biosimilar of insulin glargine and three formulations of ertugliflozin, for type 2 diabetes viz. ertugliflozin monotherapy (Steglatro), fixed-dose ertugliflozin and metformin (Segluromet) and fixed-dose ertugliflozin and sitagliptin (Steglujan). All are indicated for adults aged 18 years and older with type 2 diabetes as adjuncts to diet and exercise to improve glycemic control.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.